| INTRODUC TI ON
Primary biliary cholangitis (PBC) is a chronic autoimmune biliary disease characterised by immune-mediated destruction of intrahepatic bile ducts, cholestasis, portal inflammation and over time, a progression to end-stage biliary cirrhosis. While the histologic features can serve as diagnostic parameters, for the majority of patients, in keeping with consensus treatment guidelines, diagnosis is made based on the co-incidence of cholestatic serum liver tests and specific anti-mitochondrial antibodies. This has meant the utility of routine baseline biopsy for patients living with PBC has been questioned; yet liver biopsy findings, beyond diagnosis, may be of value in determining the risk of end-stage liver disease complications, by the understanding offered from directly evaluating stage of liver fibrosis at presentation. Yet relatively little formal evaluation exists exploring how the information gained from a baseline liver biopsy in PBC as regards to histologic stage, can contribute to long-term risk stratification for individual patients. While on its own, advanced histologic stage is an independent predictive factor for transplant-free survival conferring a 1.5-fold increased risk for liver transplantation or death, 1,2 less is known of its utility in the context of biochemical risk tools; and by extension, the value baseline liver fibrosis stage may offer for refining timely adoption of therapies designed to optimise outcomes of patients. 1, [3] [4] [5] [6] In PBC, most laboratory tools designed to allow clinical risk stratification rely on biochemical markers, including treatment response to first-line therapy with ursodeoxycholic acid (UDCA). Bilirubin and alkaline phosphatase (ALP) are surrogate markers that, either in binary, or as part of continuous models, predict outcome including transplant-free survival in patients with PBC. 7, 8 Several easily measurable non-invasive markers of fibrosis (AST/ALT ratio [AAR], AST to platelet ratio index [APRI] and FIB-4) have also been described, 5, 9, 10 and while they were initially developed and validated in patients with chronic viral hepatitis, their utility in fibrosis assessment and prediction of prognosis in PBC has also been suggested. 5 Using the large dataset afforded by the Global PBC Study Group, for which long-term outcome is reported, as well as comprehensive biochemical stratifiers, we sought to robustly explore the utility for patients offered by understanding at baseline the stage of liver fibrosis. To do so, we characterised histologic fibrosis stage in a large international cohort of PBC patients; determined whether histologic fibrosis staging improves risk stratification in addition to, and independently of, biochemical non-invasive measures of fibrosis and biochemical treatment response; evaluated the correlation between histology and biochemical non-invasive markers of fibrosis; and established optimal PBC-specific thresholds of non-invasive markers of fibrosis.
| ME THODS

| Population and study design
Data from the GLOBAL PBC Study Group database, an international cohort of patients with PBC from Europe and North America were used for this study. We included UDCA-treated patients diagnosed with PBC according to established criteria in whom a liver biopsy was performed at study entry. 11 Biopsies conducted in the 24 months prior to study entry and up to 12 months after study entry were considered as baseline in order to maximise the number of eligible patients while minimising selection bias that may already exist in those who are biopsied. These criteria were employed given established supportive data demonstrating that short-term treatment with UDCA is not associated with regression of histologic stage. 12, 13 A sub-analysis limited to patients with biopsies 6 months prior to UDCA initiation but not after, was also performed. Patients with a short follow-up (<6 months), UDCA discontinuation, unknown dates of clinical events, autoimmune hepatitis overlap syndrome or another concomitant liver disease were excluded from the study. Patients with a biopsy outside the specified time frames were also excluded.
This study was conducted in accordance with the 1975 Declaration of Helsinki. The protocol was approved by the institutional research board at all participating centres as per local regulations.
| Data collection
Baseline (study entry) was defined as the date of UDCA initiation. At study entry, the following data were collected: sex, age at diagnosis, anti-mitochondrial antibody (AMA) serological status, biochemical disease stage according to Rotterdam criteria 14 and histologic stage, for which the most commonly used methods for staging were Ludwig and Scheuer's criteria. 15, 16 Given the variability in staging systems used across centres, for the purposes of this study patients were categorised as having early fibrosis stage if reported as having stage 1 or 2 disease and advanced fibrosis stage if reported as having Pharmaceuticals, and previously from Zambon Nederland BV, and was funded by the Toronto General & Western Hospital Foundation (a not-for-profit organization) in Toronto, Canada and the Foundation for Liver and Gastrointestinal Research (a not-for-profit foundation) in Rotterdam, the Netherlands. The supporting parties had no influence on the study design, data collection and analyses, writing of the manuscript, or on the decision to submit the manuscript for publication. stage 3 or 4 disease or evidence for cirrhosis. The following laboratory parameters were collected every 6-12 months: total bilirubin, ALP, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and platelet count.
| Statistical analyses
The primary endpoint was a composite of liver transplantation and death. The influence of the various measures of fibrosis on transplant-free survival was assessed with multivariable Cox proportional hazards' regressions (hazard ratio [HR] with 95% confidence interval [CI]) while adjusting for age at the start of UDCA, sex, centre and year of diagnosis. In order to determine whether histologic fibrosis stage confers additional prognostic information to the non-invasive markers of fibrosis, histologic fibrosis stage ≥3
was inputted into the model in a forward step approach. The impact of histologic fibrosis stage was assessed as stage 1/2 vs stage 3/4 due to potential sampling and interpretative errors associated with liver biopsy. Furthermore, given that the non-invasive tests are used as measures of fibrosis, we aimed to limit the discussion to fibrosis stage. Each non-invasive marker was evaluated as a continuous and dichotomous variable according to established thresholds that have been associated with advanced fibrosis/cirrhosis (AAR = 1, APRI = 2 and FIB-4 = 3.25), 17 with the GLOBE score analysed based on age-specific thresholds. 7 Additionally, thresholds established based on the Youden index in our cohort were also employed. APRI and FIB-4 were not normally distrib- Non-invasive markers of fibrosis, namely AAR, APRI and FIB-4, were calculated at baseline. The diagnostic performance of these markers for the diagnosis of histologic fibrosis stage ≥2, stage ≥3 and stage = 4 was assessed with a receiver operating curve. Additionally, the potential correlation between Rotterdam biochemical disease stage and the GLOBE score with histologic fibrosis stage was also assessed. A grid search of the area under the receiver operating curve (AUROC) was also used to establish disease-specific thresholds for APRI and FIB-4 with a 95% sensitivity and 95% specificity for the diagnosis of cirrhosis. The negative predictive value (NPV) and positive predictive value (PPV) of the conventional thresholds and newly determined thresholds for cirrhosis were calculated. 17 Conventional thresholds of FIB-4 to exclude advanced fibrosis, namely FIB-4 ≤ 1.45, and to rule in advanced fibrosis, FIB-4 > 3.25, were used. 17 Additionally, the threshold with the highest sensitivity and specificity for the diagnosis of advanced fibrosis (stage ≥3) was determined with the Youden index (J) for each non-invasive marker of fibrosis.
Multiple imputation was completed by the Markov Chain Monte
Carlo (MCMC) method for missing data with sas version 9.4 (SAS Institute Inc). Ten imputed data sets for missing biochemical values were generated to reduce sampling variability of laboratory results at baseline and yearly thereafter up to 15 years (SAS Proc MI, MCMC method). 21 The imputation was performed based on the assumption that data were missing at random, in which variables predicting outcomes and outcomes themselves were included in the imputation model. Rubin's rules were used to estimate the parameter and standard error. 22, 23 A value of P < .05 was considered statistically significant. All analyses were two-sided and were performed using IBM spss Statistics for Windows, version 25.0 (IBM Corp.) and sas version 9.4 (SAS Institute Inc).
| RE SULTS
| Study population characteristics
A total of 1828 patients with a liver biopsy with assessment of histologic fibrosis stage at baseline were included, whose baseline characteristics are reported in Table 1 . The majority of biopsies were conducted within 6 months of study entry (n = 1496, 81.8%).
Within the cohort, 66.9% (n = 1223) had early histologic fibrosis stage (stage 1 or 2) and 33.1% (n = 605) had advanced histologic fi- (Table S1 ). While the 10-year transplant-free survival was higher for those biopsied (84.3%) compared to those not biopsied (73.8%) ( Figure S1 ), an absence of biopsy was not a significant predictor of outcome in multivariable analysis when considering age, sex, year of diagnosis, UDCA treatment and centre (HR 1.03, 95% CI 0.76-1.40, P = .85). Response rates between the biopsied group and the nonbiopsied group were similar (Table S1), and even when considering response status, having a biopsy was not predictive of outcome.
| Histologic fibrosis stage is an independent predictor of transplant-free survival
We sought to confirm that assessment of fibrosis stage histologically and/or by non-invasive testing predicts outcome. Analyses of histology were limited to stage 1/2 vs stage 3/4, but incremental changes in disease stage were associated with prognosis ( Figure 1A) . The transplant-free survival at 10 years of patients with early histologic fibrosis stage was significantly improved to those with advanced stage, 91.8% vs 70.2% (P < .001; Figure 1 ). On multivariable analysis, fibrosis stage histologically and as assessed by non-invasive markers were significantly associated with outcome with advanced histologic fibrosis stage and increased biochemical non-invasive scores being associated with an increased risk for liver transplantation or death ( Table 2) . Each of the non-invasive measures independently predicted outcome but of the ones assessed, the Rotterdam criteria were the strongest predictor of outcome (C statistic 0.78, 95% CI 0.74-0.81), followed by FIB-4 (C statistic 0.75, 95% CI 0.72-0.78), APRI (C statistic 0.71, 95% CI 0.68-0.75) and finally AAR (C statistic 0.69, 95% CI 0.65-0.72). The laboratory parameter that was most predictive of survival for Rotterdam criteria, APRI, FIB-4 and AAR were bilirubin, platelet count, platelet count and AST respectively.
For reference, the C statistic for histologic stage 1/2 vs 3/4 was 0.72 (95% CI 0.69-0.75).
In order to assess whether histologic fibrosis stage offers prognostic value beyond that gained from non-invasive markers of fibrosis, histologic fibrosis stage ≥ 3 was included in a forward step approach. Histologic fibrosis stage was included in each model and was an independent significant predictor of transplant-free survival, irrespective of the non-invasive markers of fibrosis used as continuous or categorical variables ( Table 2 ; Table S2 ). The prognostic value of non-invasive markers of fibrosis (FIB-4 and APRI) in addition to response to UDCA was also validated in the cohort of patients without a liver biopsy (Table S3 ). Figure S2 ). Furthermore, outcomes of patients with advanced histologic stage and normal ALP were also worse than those with early fibrosis and treatment response defined by the Toronto and Paris-II criteria (P < .001).
| Histologic fibrosis stage predicts prognosis despite biochemical treatment response
In multivariable analysis, a similar trend was noted ( Table 3) with Toronto criteria when advanced fibrosis was defined with these thresholds (Table S4 ). The association of baseline histologic fibrosis stage with transplant-free survival was maintained after adjusting for ALP and AAR/APRI/FIB-4 at 1 year (Table S5 ).
The method of assessment of fibrosis at baseline that was most predictive of outcome in addition to treatment response at 1 year was assessed. This revealed that assessment of fibrosis stage using FIB-4 in addition to biochemical response after 1 year of UDCA The distribution of events (liver transplantation, liver-related death or liver-unrelated death) according to biochemical response and histologic stage was significantly different between these groups ( Figure S3 ). The proportion of events that were liver-related (liver transplantation or liver-related death) was higher in those with an advanced histologic compared to those with an early histologic stage, irrespective of response status. The predominance of liver-related events in patients with advanced histologic stage, even responders, further supports the importance of assessing histologic fibrosis stage in the context of biochemical response and importantly, further emphasises that this population remains at risk for clinically relevant liver-related endpoints. Figure S4 ). 
| Biochemical non-invasive markers correlate poorly with histologic fibrosis stage in PBC
| Optimal thresholds for AAR, APRI and FIB-4 for prediction of cirrhosis in PBC patients
The thresholds with 95% sensitivity in excluding cirrhosis (stage 4)
for APRI and FIB-4 established in our cohort were 0.26 and 0.70, respectively, which were lower than the conventional thresholds (Table   S7 ). The conventional thresholds to 'rule out' advanced fibrosis/cirrhosis demonstrated low sensitivity but NPV was approximately 90% (Table S7 ). Meanwhile, the thresholds with 95% specificity for APRI and FIB-4 were 2.00 and 4.03, respectively. As for APRI, the threshold developed in our cohort was equal to the conventional threshold (2.0); whereas the FIB-4 threshold developed in our cohort was higher and demonstrated improved specificity and PPV compared to the conventional threshold of 3.25. Although these thresholds are highly sensitive and specific, cirrhosis could only be excluded or included in a small proportion of patients from the total cohort (7%-10%).
| D ISCUSS I ON
In PBC there remain challenges for patients and clinicians as regards the best approaches to understanding the disease course, the risk of adverse events and identification of those patients who will get the maximum benefit from disease modifying therapies. 24 We sought to understand how baseline liver fibrosis stage could contribute to our understanding of PBC risk. We demonstrate that histologic fibrosis stage categorised as early (stage 1/2) vs advanced (stage 3/4) fibrosis is an independent predictor of transplant-free survival while adjusting for the non-invasive markers, and importantly, that its association with outcome persists after 1 year, despite treatment response, that is, it adds prognostic information to a group with biochemical response to first-line treatment, potentially not presently readily identified. We further show that histologic fibrosis stage cor- 20, 27 Similar to prior smaller series, 28 our large cohort study confirmed suboptimal correlation between histologic fibrosis stage and non-invasive markers. These correlations are weaker than previously described, which may be explained by our large sample size, differences in fibrosis staging systems used between studies, or differences in patient cohorts included, with some prior reports including patients with PBC-AIH overlap syndrome, prolonged UDCA use (6.9 years), and those receiving second-line adjunctive therapies in addition to UDCA. 29 These data are in contrast to stronger correlations reported between APRI and FIB-4 and histologic fibrosis stage in other aetiologies of liver disease such as viral hepatitis; a recent systematic review reported an AUROC to detect cirrhosis of 0.84 for APRI and 0.87 for FIB-4 in patients with chronic hepatitis C. 30 We established diseasespecific thresholds for APRI and FIB-4 for excluding and including cirrhosis. It is not clear how much utility these will prove to have; only a small percentage (7%-10%) of the total population met these criteria, emphasising the suboptimal correlation with histologic fibrosis stage.
Several potential explanations for discordance between liver biopsies and biochemical non-invasive measures of fibrosis have been reported in the literature and include factors such as variability in necroinflammatory burden across different aetiologies of liver disease, for example in HDV/HBV viral co-infection as compared to monoinfection, 31 sampling error, 32 inter-observer variability between pathologists 33 and timing of non-invasive measure assessment relative to the time of biopsy. 34 Although sampling bias and inter-observer variability could not be completely excluded, the large sample size of our cohort can minimise its potential influence on our findings. Furthermore, staging was assessed as early and advanced to account for interpretive or inter-observer variability, and some of the potentially associated confounding factors associated with it, such as centre and diagnosis year, which were adjusted for in multivariable analyses. Additionally, correlation between histologic stage and biochemical non-invasive measures of fibrosis is similar when the cohort is limited to biopsies 6 months prior to UDCA initiation.
Our study represents a large cohort of well-characterised patients with PBC, for whom histologic staging was available with contemporaneous biochemical variables. Prior studies included smaller cohorts with heterogeneous patient populations that may have introduced greater bias into evaluations. Despite the size of our study aiding investigation of this rare and slowly progressive disease, we wish to have changed aspects were we able to. For example, the indications for biopsy were not available and nor were additional histologic variables other than fibrosis stage including inflammatory burden, ductopenia and sinusoidal fibrosis, which may also be associated with prognosis in PBC. Although biochemical data at baseline were not available for all patients due to the real-life nature of the cohort, valid multiple imputation methods were implemented to minimise bias. In addition, biopsy data at baseline were only available for a subset of patients within the Global PBC Study Group database, although an effort was made to consider a potential bias by comparing the patients included in the study to those who did not have a biopsy. While those who were biopsied did tend to have higher liver tests, they did not have overlap syndrome with autoimmune hepatitis by diagnosis, nor did they meet Paris criteria for this, and their survival was comparable to those without a biopsy.
In conclusion, in evaluating the utility of baseline liver biopsy in patients with PBC, we demonstrate that an assessment of fibrosis stage, be it histologically or via non-invasive measures of fibrosis, adds meaningful information to individualised patient risk stratification beyond biochemical treatment response after 1 year. While liver biopsy is not indicated for diagnosis, our data highlights the importance of incorporating available technologies and risk stratifiers for liver fibrosis, alongside biochemical markers of cholestatic therapy response, to best identify patients at risk of poor outcomes and in need of second-line therapies.
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